keyword
https://read.qxmd.com/read/38617965/revealing-the-active-ingredients-and-mechanism-of-p-sibiricumm-in-non-small-cell-lung-cancer-based-on-uplc-q-tof-ms-ms-network-pharmacology-and-molecular-docking
#21
JOURNAL ARTICLE
Kaili Guo, Yu Jiang, Wei Qiao, Panpan Yuan, Miao Xue, Jiping Liu, Hao Wei, Bin Wang, Xingmei Zhu
The alcohol extraction of P. sibiricum has exhibited significant inhibitory effects on the production of free radicals and the proliferation of non-small-cell lung carcinoma (NSCLC) A549 cells. Despite the diverse components found in alcohol extraction of P. sibiricum and its multiple targets, the active components and associated targets remain largely unidentified. Hence, there is a need for additional investigation into the pharmacodynamic elements and mechanisms of action. This study aimed to analyze and identify the components responsible for the anti-tumor activity of alcohol extraction from P...
April 15, 2024: Heliyon
https://read.qxmd.com/read/38616411/phase-1-placebo-controlled-single-ascending-dose-trial-to-evaluate-the-safety-pharmacokinetics-and-effect-on-altered-states-of-consciousness-of-intranasal-bpl-003-5-methoxy-n-n-dimethyltryptamine-benzoate-in-healthy-participants
#22
JOURNAL ARTICLE
James Jonathan Rucker, Claire Roberts, Mathieu Seynaeve, Allan H Young, Ben Suttle, Takahiro Yamamoto, Anna O Ermakova, Fiona Dunbar, Frank Wiegand
AIMS: To investigate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of BPL-003, a novel intranasal benzoate salt formulation of 5-methoxy- N,N -dimethyltryptamine (5-MeO-DMT), in healthy participants. METHODS: In all, 44 psychedelic-naïve participants enrolled in the double-blind, placebo-controlled single ascending dose study (1-12 mg BPL-003). Concentrations of 5-MeO-DMT and its pharmacologically active metabolite, bufotenine, were determined in plasma and urine...
April 14, 2024: Journal of Psychopharmacology
https://read.qxmd.com/read/38615798/ultramicronized-n-palmitoylethanolamine-associated-with-analgesics-effects-against-persistent-pain
#23
REVIEW
Stefania Nobili, Laura Micheli, Elena Lucarini, Alessandra Toti, Carla Ghelardini, Lorenzo Di Cesare Mannelli
Current epidemiological data estimate that one in five people suffers from chronic pain with considerable impairment of health-related quality of life. The pharmacological treatment is based on first- and second-line analgesic drugs, including COX-2 selective and nonselective nonsteroidal anti-inflammatory drugs, paracetamol, antidepressants, anti-seizure drugs and opioids, that are characterized by important side effects. N-palmitoylethanolamine (PEA) is a body's own fatty-acid ethanolamide belonging to the family of autacoid local injury antagonist amides...
April 12, 2024: Pharmacology & Therapeutics
https://read.qxmd.com/read/38615429/derivatization-free-determination-of-chiral-plasma-pharmacokinetics-of-mdma-and-its-enantiomers
#24
JOURNAL ARTICLE
Dino Luethi, Deborah Rudin, Isabelle Straumann, Jan Thomann, Isidora Avedisian, Matthias E Liechti, Urs Duthaler
3,4-Methylenedioxymethamphetamine (MDMA) is an entactogen with therapeutic potential. The two enantiomers of MDMA differ regarding their pharmacokinetics and pharmacodynamics but the chiral pharmacology of MDMA needs further study in clinical trials. Here, an achiral and an enantioselective high performance liquid chromatography-tandem mass spectrometry method for the quantification of MDMA and its psychoactive phase I metabolite 3,4-methylenedioxyamphetamine (MDA) in human plasma were developed and validated...
April 9, 2024: Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences
https://read.qxmd.com/read/38614299/the-drug-specific-properties-of-hypoxia-inducible-factor-prolyl-hydroxylase-inhibitors-in-mice-reveal-a-significant-contribution-of-the-kidney-compared-to-the-liver-to-erythropoietin-induction
#25
JOURNAL ARTICLE
Taku Nakai, Daisuke Saigusa, Koichiro Kato, Tomoko Fukuuchi, Seizo Koshiba, Masayuki Yamamoto, Norio Suzuki
AIMS: Kidney disease often leads to anemia due to a defect in the renal production of the erythroid growth factor erythropoietin (EPO), which is produced under the positive regulation of hypoxia-inducible transcription factors (HIFs). Chemical compounds that inhibit HIF-prolyl hydroxylases (HIF-PHs), which suppress HIFs, have been developed to reactivate renal EPO production in renal anemia patients. Currently, multiple HIF-PH inhibitors, in addition to conventional recombinant EPO reagents, are used for renal anemia treatment...
April 11, 2024: Life Sciences
https://read.qxmd.com/read/38614153/cubic-liquid-crystals-containing-propolis-flavonoids-as-in-situ-thermo-sensitive-hydrogel-depots-for-periodontitis-treatment-preparation-pharmacodynamics-and-therapeutic-mechanisms
#26
JOURNAL ARTICLE
Maomao Tang, Jiaxin Li, Guichun Wang, Yuxiao Wang, Chengjun Peng, Xiangwei Chang, Yaotian Tao, Jian Guo, Shuangying Gui
Propolis has a long ethnopharmacological history for oral periodontal diseases treatment. Propolis flavonoids are main active components for anti-inflammation and tissue protection. However, the intractable dissolution properties of propolis flavonoids and complex oral environment pose great challenges for periodontal delivery. In addition, the therapeutic mechanism as well as the therapeutic correlation of inflammation resolution and tissue regeneration remain unclear for propolis flavonoids. In this study, we constructed an in situ thermosensitive depot systems using total flavonoids from propolis-loaded cubic liquid crystals (TFP-CLC) hydrogel for periodontal delivery...
April 11, 2024: European Journal of Pharmaceutical Sciences
https://read.qxmd.com/read/38614151/modification-of-the-phenyl-ring-b-of-phenyl-4-2-oxoimidazolidin-1-yl-benzenesulfonates-by-pyridinyl-moiety-leads-to-novel-antimitotics-targeting-the-colchicine-binding-site
#27
JOURNAL ARTICLE
Vincent Ouellette, Chahrazed Bouzriba, Atziri Corin Chavez Alvarez, Geneviève Hamel-Côté, Sébastien Fortin
A series of 8 novel pyridinyl 4-(2-oxoimidazolidin-1-yl)benzenesulfonates (PYRIB-SOs) were designed, prepared and evaluated for their mechanism of action. PYRIB-SOs were found to have antiproliferative activity in the nanomolar to submicromolar range on several breast cancer cell lines. Moreover, subsequent biofunctional assays indicated that the most potent PYRIB-SOs 1-3 act as antimitotics binding to the colchicine-binding site (C-BS) of α, β-tubulin and that they arrest the cell cycle progression in the G2/M phase...
April 11, 2024: Bioorganic & Medicinal Chemistry Letters
https://read.qxmd.com/read/38612796/unified-methodology-for-the-primary-preclinical-in-vivo-screening-of-new-anticoagulant-pharmaceutical-agents-from-hematophagous-organisms
#28
JOURNAL ARTICLE
Maria A Kostromina, Elena A Tukhovskaya, Elvira R Shaykhutdinova, Yuliya A Palikova, Viktor A Palikov, Gulsara A Slashcheva, Alina M Ismailova, Irina N Kravchenko, Igor A Dyachenko, Evgeniy A Zayats, Yuliya A Abramchik, Arkady N Murashev, Roman S Esipov
The development of novel anticoagulants requires a comprehensive investigational approach that is capable of characterizing different aspects of antithrombotic activity. The necessary experiments include both in vitro assays and studies on animal models. The required in vivo approaches include the assessment of pharmacokinetic and pharmacodynamic profiles and studies of hemorrhagic and antithrombotic effects. Comparison of anticoagulants with different mechanisms of action and administration types requires unification of the experiment scheme and its adaptation to existing laboratory conditions...
April 3, 2024: International Journal of Molecular Sciences
https://read.qxmd.com/read/38612661/applications-of-flow-cytometry-in-drug-discovery-and-translational-research
#29
REVIEW
Sumana Ullas, Charles Sinclair
Flow cytometry is a mainstay technique in cell biology research, where it is used for phenotypic analysis of mixed cell populations. Quantitative approaches have unlocked a deeper value of flow cytometry in drug discovery research. As the number of drug modalities and druggable mechanisms increases, there is an increasing drive to identify meaningful biomarkers, evaluate the relationship between pharmacokinetics and pharmacodynamics (PK/PD), and translate these insights into the evaluation of patients enrolled in early clinical trials...
March 29, 2024: International Journal of Molecular Sciences
https://read.qxmd.com/read/38611824/analgesic-peptides-from-natural-diversity-to-rational-design
#30
REVIEW
Katarzyna Gach-Janczak, Monika Biernat, Mariola Kuczer, Anna Adamska-Bartłomiejczyk, Alicja Kluczyk
Pain affects one-third of the global population and is a significant public health issue. The use of opioid drugs, which are the strongest painkillers, is associated with several side effects, such as tolerance, addiction, overdose, and even death. An increasing demand for novel, safer analgesic agents is a driving force for exploring natural sources of bioactive peptides with antinociceptive activity. Since the G protein-coupled receptors (GPCRs) play a crucial role in pain modulation, the discovery of new peptide ligands for GPCRs is a significant challenge for novel drug development...
March 29, 2024: Molecules: a Journal of Synthetic Chemistry and Natural Product Chemistry
https://read.qxmd.com/read/38610965/-ianus-bifrons-the-two-faces-of-metformin
#31
REVIEW
Umberto Goglia, Iderina Hasballa, Claudia Teti, Mara Boschetti, Diego Ferone, Manuela Albertelli
The ancient Roman god Ianus was a mysterious divinity with two opposite faces, one looking at the past and the other looking to the future. Likewise, metformin is an "old" drug, with one side looking at the metabolic role and the other looking at the anti-proliferative mechanism; therefore, it represents a typical and ideal bridge between diabetes and cancer. Metformin (1,1-dimethylbiguanidine hydrochloride) is a drug that has long been in use for the treatment of type 2 diabetes mellitus, but recently evidence is growing about its potential use in other metabolic conditions and in proliferative-associated diseases...
March 26, 2024: Cancers
https://read.qxmd.com/read/38609673/five-multivariate-duchenne-muscular-dystrophy-progression-models-bridging-six-minute-walk-distance-and-mri-relaxometry-of-leg-muscles
#32
JOURNAL ARTICLE
Deok Yong Yoon, Michael J Daniels, Rebecca J Willcocks, William T Triplett, Juan Francisco Morales, Glenn A Walter, William D Rooney, Krista Vandenborne, Sarah Kim
The study aimed to provide quantitative information on the utilization of MRI transverse relaxation time constant (MRI-T2 ) of leg muscles in DMD clinical trials by developing multivariate disease progression models of Duchenne muscular dystrophy (DMD) using 6-min walk distance (6MWD) and MRI-T2 . Clinical data were collected from the prospective and longitudinal ImagingNMD study. Disease progression models were developed by a nonlinear mixed-effect modeling approach. Univariate models of 6MWD and MRI-T2 of five muscles were developed separately...
April 12, 2024: Journal of Pharmacokinetics and Pharmacodynamics
https://read.qxmd.com/read/38607457/understanding-and-quantifying-network-robustness-to-stochastic-inputs
#33
JOURNAL ARTICLE
Hwai-Ray Tung, Sean D Lawley
A variety of biomedical systems are modeled by networks of deterministic differential equations with stochastic inputs. In some cases, the network output is remarkably constant despite a randomly fluctuating input. In the context of biochemistry and cell biology, chemical reaction networks and multistage processes with this property are called robust. Similarly, the notion of a forgiving drug in pharmacology is a medication that maintains therapeutic effect despite lapses in patient adherence to the prescribed regimen...
April 12, 2024: Bulletin of Mathematical Biology
https://read.qxmd.com/read/38606909/biomarker-guided-drug-development-provides-value-for-patients-payers-and-drug-developers-lessons-learned-from-25-years-in-the-biomarker-industry
#34
REVIEW
Alexander L Reese-Petersen, Helene W Breisnes, Daniel Gabor, Sarah R Rønnow, Bruna Manoel, Mayuur Bajaj, Claus S von Arenstorff, Elijah Aighobahi, Rune Vestermark, Morten A Karsdal
IntroductionThere is an urgent, persistent, need for better biomarkers in clinical drug development. More informative biomarkers can increase the likelihood of drug advancement or approval, and implementing biomarkers increases the success rate in drug development. Biomarkers may guide decisions and allow resources to be directed to the projects most likely to succeed. However, biomarkers that are validated to high standards are needed, reflecting biological and pathological processes accurately. Such biomarkers are needed to develop treatments faster, and to improve and guide clinical trial design by selecting and de-selecting patients...
April 12, 2024: Biomarkers: Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals
https://read.qxmd.com/read/38606777/apilimod-dimesylate-in-c9orf72-amyotrophic-lateral-sclerosis-a-randomized-phase-2a-clinical-trial
#35
JOURNAL ARTICLE
Suma Babu, Katharine A Nicholson, Jeffrey D Rothstein, Andrea Swenson, Paul J Sampognaro, Pravin Pant, Eric A Macklin, Susan Spruill, Sabrina Paganoni, Tania F Gendron, Mercedes Prudencio, Leonard Petrucelli, Darrell Nix, Sean Landrette, Esther Nkrumah, Keith Fandrick, Joan Edwards, Peter R Young
Apilimod dimesylate is a first-in-class phosphoinositide kinase, FYVE-type zinc finger containing (PIKfyve) inhibitor with favourable clinical safety profile and has demonstrated activity in preclinical C9orf72 and TDP-43 amyotrophic lateral sclerosis models. In this amyotrophic lateral sclerosis clinical trial, the safety, tolerability, CNS penetrance, and modulation of pharmacodynamic target engagement biomarkers were evaluated. This Phase 2a, randomized, double-blind, placebo-controlled, biomarker-endpoint clinical trial was conducted in four USA centres (ClinicalTrials...
April 12, 2024: Brain
https://read.qxmd.com/read/38606250/steroid-premedication-might-protect-from-postoperative-erythema-nodosum-leprosum-in-leprosy-a-case-report
#36
Shweta B Hembrom, Ghazal Ahmed, Habib Md R Karim, Vineeta Singh, Priyanka Rai, Suchita V Meshram
Leprosy is known for its diverse pathophysiologic involvement and resulting multisystemic manifestation and morbidities. Despite global efforts to eliminate this public health illness, it is still prevalent in some Asian and European countries. Perioperative management of a leprosy patient is challenging owing to the indirect and direct involvement of the airway, respiratory, and cardiac systems; treatment-related side-effects involving the hepato-renal systems affecting the anesthesia techniques and drugs pharmacokinetic and pharmacodynamics...
March 2024: Curēus
https://read.qxmd.com/read/38606170/a-comprehensive-review-of-the-botany-phytochemistry-pharmacology-and-toxicology-of-murrayae-folium-et-cacumen
#37
REVIEW
Yue Qi, Lin Wang, Na Wang, Siyi Wang, Xu Zhu, Tie Zhao, Qinghua Jiang
Ethnopharmacological relevance: Murrayae Folium et Cacumen (MFC) is a plant considered to be a traditional Chinese medicine with culinary value as well. The dry leaves and twigs of Murraya paniculata and M. exotica are used to treat stomach aches, rheumatism, toothaches, swelling, and insect and snake bites. They are also used to prepare spicy chicken dishes. Aim of the review: This review comprehensively summarizes the available information on the botanical characterization, phytochemistry, pharmacological activities, pharmacodynamics, pharmacokinetics, and toxicity of MFC...
2024: Frontiers in Pharmacology
https://read.qxmd.com/read/38604815/oral-pd-l1-inhibitor-gs-4224-selectively-engages-pd-l1-high-cells-and-elicits-pharmacodynamic-responses-in-patients-with-advanced-solid-tumors
#38
JOURNAL ARTICLE
Jared M Odegard, Ahmed A Othman, Kai-Wen Lin, Adele Y Wang, Jonathan Nazareno, Oh Kyu Yoon, John Ling, Latesh Lad, P Rod Dunbar, Dung Thai, Edmond Ang, Nicholas Waldron, Sanjeev Deva
BACKGROUND: Checkpoint inhibitors targeting the programmed cell death 1 (PD-1)/programmed cell death 1 ligand 1 (PD-L1) pathway are effective therapies in a range of immunogenic cancer types. Blocking this pathway with an oral therapy could benefit patients through greater convenience, particularly in combination regimens, and allow flexible management of immune-mediated toxicities. METHODS: PD-L1 binding activity was assessed in engineered dimerization and primary cell target occupancy assays...
April 11, 2024: Journal for Immunotherapy of Cancer
https://read.qxmd.com/read/38604813/autologous-human-preclinical-modeling-of-melanoma-interpatient-clinical-responses-to-immunotherapeutics
#39
JOURNAL ARTICLE
Yee Peng Phoon, Jared E Lopes, Lukas W Pfannenstiel, Claudia Marcela Diaz-Montero, Ye F Tian, Marc S Ernstoff, Pauline Funchain, Jennifer S Ko, Raymond Winquist, Heather C Losey, Jan Joseph Melenhorst, Brian R Gastman
BACKGROUND: Despite recent advances in immunotherapy, a substantial population of late-stage melanoma patients still fail to achieve sustained clinical benefit. Lack of translational preclinical models continues to be a major challenge in the field of immunotherapy; thus, more optimized translational models could strongly influence clinical trial development. To address this unmet need, we designed a preclinical model reflecting the heterogeneity in melanoma patients' clinical responses that can be used to evaluate novel immunotherapies and synergistic combinatorial treatment strategies...
April 11, 2024: Journal for Immunotherapy of Cancer
https://read.qxmd.com/read/38602417/a-phase-1-study-of-kin-3248-an-irreversible-small-molecule-pan-fgfr-inhibitor-in-patients-with-advanced-fgfr-2-3-driven-solid-tumors
#40
JOURNAL ARTICLE
Benjamin Garmezy, Mitesh J Borad, Rastislav Bahleda, Cesar A Perez, Li-Tzong Chen, Shumei Kato, Do-Youn Oh, Paul Severson, Betty Y Tam, Cheng Quah, James J Harding
BACKGROUND: Despite efficacy of approved FGFR inhibitors, emergence of polyclonal secondary mutations in the FGFR kinase domain leads to acquired resistance. KIN-3248 is a selective, irreversible, orally bioavailable, small molecule inhibitor of FGFR1-4 that blocks both primary oncogenic and secondary kinase domain resistance FGFR alterations. MATERIALS AND METHODS: A first-in-human, Phase 1 study of KIN-3248 was conducted in advanced solid tumors patients harboring FGFR2 and/or FGFR3 gene alterations (NCT05242822)...
April 11, 2024: Cancer Res Commun
keyword
keyword
6597
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.